Ipilimumab

Source: The website of the National Cancer Institute (http://www.cancer.gov)
Ipilimumab is approved to treat:

Ipilimumab is also being studied in the treatment of other types of cancer.


This study says: The median overall survival in the ipilimumab + gp100 arm was 10.0 months compared with 6.4 months in the gp100 arm…
The prescribing information for ipilimumab includes a boxed warning regarding the potential for severe and fatal immune-mediated adverse reactions resulting from T-cell activation and proliferation. These reactions may involve any organ system; however…

Ipilimumab Injection

Source: MedlinePlus

IMPORTANT WARNING:
Ipilimumab injection may cause severe or life-threatening side effects. This includes inflammation of the intestine, which may cause tears in its walls; inflammation of the liver, which may cause severe liver damage; inflammation of the skin, which may cause a serious skin reaction; inflammation of the nerves, which may cause paralysis (loss of ability to move all or part of the body); inflammation of certain glands, which may affect how the glands work; or inflammation of the eyes.You may develop these symptoms during your treatment or during the first few weeks or months after you finish your treatment.

Why is this medication prescribed?
Ipilimumab injection is used to treat melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Ipilimumab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.


Published Clinical Trials / Studies / Reviews
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events


Cancer Treatment Options 

Updated September 2024

Please share this page to help others

©2012-2024 cancerireland.ie Proudly powered by WordPress